NewsRoom Articles - Page 131 of 231

MondayMay 02, 2022 1:59 pm

Researchers May Have Found New Way to Slow Progression of Cancer

Scientists at the University of Sussex may have discovered a way to decrease the speed at which glioblastoma grows and strengthen potential treatments for the brain tumor. Glioblastoma is a common tumor found in adults. This aggressive tumor is often resistant to treatment, making it fatal. In their new study, researchers have shown that differentiation therapy may be used to limit the growth of the tumors and turn off the malignant properties of cancerous cells. They suggest that an inhibitor drug known to target certain cell proteins may be used to make glioblastoma treatments more effective. Professor Georgios Giamas of…

FridayApr 29, 2022 12:31 pm

Research Highlights the High Economic Cost of PTSD

New research has found that the national economic burden of post-traumatic stress disorder (“PTSD”) exceeds the costs of other mental disorders such as depression and anxiety. Researchers estimate the cost of post-traumatic stress disorder for 2018 to be roughly $232 billion. They highlighted the need for more effective therapies, to increase awareness of post-traumatic stress disorder, and for the expansion of new strategies to decrease the economic and clinical burden of mental health disorders. The researchers stated that the PTSD economic burden in America shown in the study was “astonishing” and highlighted the urgency for private and public stakeholders to…

ThursdayApr 28, 2022 1:54 pm

Colorado Patients Reap Benefits of Ketamine Treatments for Depression

Patients with severe depression in the state of Colorado who haven’t been successful in managing their indication with antidepressants have turned to ketamine. Ketamine is a prescription drug used by veterinarians and medical practitioners as an anesthetic. Researchers at Yale have found that this drug prompts the brain to make new neural connections, allowing it to form more positive behaviors and thoughts. A new community health program, the Mental Health Center of Denver, has been providing ketamine therapy. It is currently the only clinic in the state offering this particular therapy and is among the few in the country servicing…

ThursdayApr 28, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeutic Cybin is currently developing CYB004 for the treatment of anxiety disorders The new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT. "In many studies, DMT has shown to be a promising and…

WednesdayApr 27, 2022 12:57 pm

Study Evaluates Possible Link Between Parkinson’s Disease, Autoimmune Malfunction

A new study is looking into whether autoimmunity is a trigger for Parkinson’s disease. Parkinson’s disease is a brain disorder that causes an individual to have issues with coordination, balance and walking. This progressive disorder also causes stiffness and shaking, and is known to worsen over time. Figures show that about one million individuals in America suffer from Parkinson’s disease. On a global scale, the disease is said to affect more than 10 million individuals. Thus far, research has shown that before the disease progresses to a loss in motor skills, patients may experience changes in their sense of smell,…

TuesdayApr 26, 2022 2:15 pm

Depression Causes Lasting Physiological Alterations to Immunity Cells

New research has discovered a link between changes in the function and shape of immune cells, mechanical changes in blood cells and persistent depressive disorders. Depressive disorders are one of the primary causes of disability around the globe. Depression is known to cause an increase in the production of stress hormones, including glucocorticoids, as well as cause chronic low-grade inflammation. These effects can interfere with immune cell structure. Persistent depressive disorder can impact an individual for a lifetime and is known to last for at least two years. The eye-opening study was carried out by Dr. Andreas Walther while working…

MondayApr 25, 2022 11:17 am

Plants Could Unlock Future Cancer Therapies

Researchers have highlighted the important role that some plants play in the manufacture of cancer drugs and why these new sources and plant resources need to be maintained in an effort to avoid overexploitation. For instance, Kew Gardens researcher Melanie-Jayne Howes stated that a chemical found in the Pacific yew tree was used to develop an anti-cancer drug called paclitaxel, which is effective in the treatment of breast and ovarian cancers. However, the chemical is produced in low volumes, which led to many trees being cut down in order to manufacture these drugs. Now, the Pacific yew tree is classified…

FridayApr 22, 2022 11:21 am

Scientists Stop Memory Decay by Administering Nasal Therapy to Mice

According to estimates from the Centers for Disease Control and Prevention (CDC), around 6 million people in the United States suffer from Alzheimer’s disease and related dementias. Of the Americans afflicted with this debilitating condition, there are 200,000 people under 60 with early-onset Alzheimer’s. Scientists believe that Alzheimer’s is caused when proteins build up abnormally in and around brain cells, either forming plaque around the brain cells or tangles within the cells. A protein called amyloid forms plaque around the cells while a protein called tau forms tangles in the cells. We still don’t know what leads to this buildup…

ThursdayApr 21, 2022 2:31 pm

Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions

New research has found that examining the brain structure of patients with recent onset of depression and psychosis may help identify those who are more likely to have poor outcomes. The researchers believe that physicians will be able to offer these patients more effective, targeted treatments by identifying them while in the early stages of their disorder. For their study, the researchers utilized data from the Pronia study. The Pronia study is a cohort study that is looking into prognostic tools for psychoses. The group included 300 patients with recent onset depression and recent onset psychosis in its research. The…

ThursdayApr 21, 2022 9:00 am

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a potential new treatment for multiple sclerosis and other conditions,” and their Joint Homing Peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, “enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity….They may be…